A Case Report of Posttransplant Lymphoproliferative Disorder After AstraZeneca Coronavirus Disease 2019 Vaccine in a Heart Transplant Recipient.
Transplant Proc
; 54(6): 1575-1578, 2022.
Article
em En
| MEDLINE
| ID: mdl-34702598
ABSTRACT
We report a case of a heart transplant recipient who presented with a rapidly growing Epstein-Barr virus (EBV)-positive, diffuse large B-cell lymphoma 7 days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. Because of the atypical radiologic presentation, the initial tentative diagnosis was a mediastinal abscess. This observation indicates a potential risk of EBV reactivation after coronavirus disease 2019 (COVID-19) vaccination, which might lead to or aggravate the presentation of posttransplant lymphoproliferative disorder in transplantation patients. Transplant surgeons should be aware of the potential immunomodulatory effects of the COVID-19 vaccination.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Transplante de Coração
/
Infecções por Vírus Epstein-Barr
/
COVID-19
/
ChAdOx1 nCoV-19
/
Transtornos Linfoproliferativos
Limite:
Humans
Idioma:
En
Ano de publicação:
2022